Grifols, S.A.
https://www.grifols.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Grifols, S.A.
Finance Watch: Q2 Ends, Q3 Begins With Latest Group Of VC Mega-Rounds
Private Company Edition: June ended with Formation Bio’s $372m series D round and July began with Beacon’s $170m series B. Also, Curie.Bio raised a $380m fund, Freeflow Ventures emerged with $90m across multiple funds and EvolutionaryScale raised a $142m seed round.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
Grifols Aims For Largely Untapped Market With Successful Fibrinogen Deficiency Study
The Phase III trial of BT524 produced positive topline results in patients with acquired fibrinogen deficiency, potentially making it the first fibrinogen concentrate to win US FDA approval for that indication.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Company Information
- Industry
- Pharmaceuticals
-
Medical Devices
- Diagnostic Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
-
- Alpha Therapeutic Corporation
- Biotest AG
- Goetech LLC
- GigaGen, Inc.
- Grifols Therapeutics, Inc.
- MedKeeper
- Talecris Biotherapeutics Inc.
- Haema AG.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice